Navigation Links
European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
Date:10/24/2008

00 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit http://www.boehringer-ingelheim.com.

Duloxetine for major depressive episodes, diabetic peripheral neuropathic pain and generalised anxiety disorder is marketed by Lilly and Boehringer Ingelheim in all countries included in the partnership under the brand name Cymbalta, except for Germany, Greece, Italy and Spain. In Germany, Lilly and Boehringer Ingelheim market duloxetine for major depressive episodes under the brand name Cymbalta, and market the product for diabetic peripheral neuropathic pain as Ariclaim(R). In Greece, Italy and Spain Lilly markets the product as Cymbalta and Boehringer Ingelheim markets the product as Xeristar(R). In the United States, Cymbalta is marketed by Lilly and Quintiles. In Japan, duloxetine is co-developed and co-marketed by Lilly and Shionogi & Co., Ltd.

Duloxetine for stress urinary incontinence is marketed by Lilly under the brand name Yentreve(R).

(1) Russell, IJ, et al. Efficacy and Safety of Duloxetine for Treatment of Fibromyalgia in Patients With or Without Major Depressive Disorder: Results From A Six-Month, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Trial, Pain. 2008.

(2) Arnold, L, et al. A Randomized, Double-Blind, Placebo Controlled Trial of Duloxetine in the Treatment of Women with Fibromyalgia With or Without Major Depressive Disorder. Pain. 2005; 119 (1-3): 5-15

(3) Arnold, L, et al. A Double-Blind, Multicenter Trial Comparing Duloxetine with Placebo in the Treatment of Fi
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
6. European Centre for Modern Drug Discovery Established in Hamburg
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Xencor, Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... of Debra Zack , M.D., Ph.D., vice ... Lloyd Rowland , senior vice president, chief compliance ... expertise in biologics clinical development and medical affairs ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
(Date:9/1/2014)... 2014 Reportlinker.com announces that a new ... India Solid Waste Management Vehicles Market ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In India ... bodies responsible for complete handling and regulation of ... around 135,000 MT solid waste is generated daily ...
(Date:8/31/2014)... Available spectra is similar for all L-series ... of a wide range of plants. The spectra ... patented and pending wide spectrum technology. The single ... applications in contrast to growth spectra made from ... a large variety of differently sized and shaped ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... Identify Potential Initiation Dosing Regimen , ... palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant ... of a 13-week study presented today (1). Statistical ... and 150 mg equivalent [eq.a]), when given every 4 ...
... the Journal Blood for the American Society of Hematology Annual ... Dec. 10 Alfacell Corporation (Nasdaq: ACEL ) ... abstracts in Blood (2008 112: Abstract 4205 & ... (R-Amph) show anti-tumor activity in chronic lymphocytic leukemia (CLL) and ...
... Calif., Dec. 10 Valeant,Pharmaceuticals International (NYSE: ... signed a,definitive agreement to acquire Dow Pharmaceutical Sciences, ... the development of topical,products on a proprietary basis, ... The transaction significantly enhances Valeant,s,dermatology franchise in the ...
Cached Biology Technology:Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 2Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 3Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 4Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 5Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 6Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 7Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 8Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 9Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 2Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 3Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 4Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 5
(Date:9/2/2014)... Passerine birds, also known as perching birds, that migrate ... they do in autumn to reach their destinations. This ... birds that only make short migratory flights, says researcher ... journal Behavioral Ecology and Sociobiology . , ... used a tracking radar to measure over three years ...
(Date:9/2/2014)... Air pollution regulations over the last decade in Taiyuan, ... there, accounting for a greater than 50% reduction in ... 2001 and 2010, according to researchers at the Columbia ... School of Public Health, the Shanxi Medical University, the ... and Shanghai Fudan University School of Public Health. , ...
(Date:9/2/2014)... stride; others are done in by it. New research ... this so-called stress gap in mice with very similar ... to better understand the development of psychiatric disorders such ... has unique experiences as it goes through its life. ... the expression of genes, and as a result, affect ...
Breaking Biology News(10 mins):Migrating birds sprint in spring, but take things easy in autumn 2Clean air halves health costs in Chinese city 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... speech President Bush said technology is the best way to ... Energy Joint Genome Institute (DOE JGI) is directing the technology ... will lead to cheaper and easier to produce biofuels. ... molecular biology we can generate diagnostic fingerprints, Environmental Genomic Tags ...
... the March 24 Cell reports the discovery of a ... could offer a potential new target for countermeasures against ... therapies might have the potential to protect against anthrax ... have lost their therapeutic value, they added. , The ...
... Scientists have for many years debated the cause of ... Papagrigorakis and colleagues using DNA collected from teeth from ... as the disease responsible for this devastating epidemic. The ... Journal of Infectious Diseases (IJID) published by Elsevier on ...
Cached Biology News:Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy 2Driver of anthrax toxicity could lead to late-stage therapy 2Typhoid fever led to the fall of Athens 2
... Reagents are complete ready-to-use reagents for the ... is specifically formulated for the isolation of ... is specifically formulated for the isolation of ... with DNAzol Reagents can be used for ...
Apoptosis Detection Systems and Reagents...
... rodent oral gavage feature soft rubber tips ... trauma. Plus they are disposable, to eliminate ... of cross-contamination. Diameter: ... Length: ...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Biology Products: